

Identifying the young person at risk of psychosis

STANLEY V. CATTS MD, FRANZCP

References

1. WHO International Consortium in Psychiatric Epidemiology. Cross-national comparisons of prevalence and correlates of mental disorders. *Bull World Health Organ* 2000; 78: 413-426.
2. Kessler RC, Amminger GP, Aguilar-Gaxiola S, Alonso J, Lee S, Ustun TB. Age of onset of mental disorders: a review of recent literature. *Curr Opin Psychiatry* 2007; 20: 359-364.
3. Perala J, Suvisaari J, Saarni SI, et al. Lifetime prevalence of psychotic and bipolar I disorders in a general population. *Arch Gen Psychiatry* 2007; 64: 19-28.
4. Murray C, Lopez A, eds. *The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020*. Cambridge: Harvard University Press; 1996.
5. Videbech P, Ravnkilde B. Hippocampal volume and depression: a meta-analysis of MRI studies. *Am J Psychiatry* 2004; 161: 1957-1966.
6. Harrigan SM, McGorry PD, Krstev H. Does treatment delay in first-episode psychosis really matter? *Psychol Med* 2003; 33: 97-110.
7. Wiersma D, Nienhuis FJ, Slooff CJ, Giel R. Natural course of schizophrenic disorders: a 15-year follow-up of a Dutch incidence cohort. *Schizophr Bull* 1998; 24: 75-85.
8. Robinson D, Woerner MG, Alvir JM, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. *Arch Gen Psychiatry* 1996; 56: 241-247.
9. Lieberman JA, Perkins D, Belger A, et al. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. *Biol Psychiatry* 2001; 50: 884-897.
10. Hafner H, Maurer K, Loffler W, et al. Onset and prodromal phase as determinants of the course. In: Gattaz WF, Hafner H, eds. *Search for the causes of schizophrenia (Vol. IV: Balance of the century)*. Darmstadt: Steinkopff; 1999: 35-58.
11. Hafner H, Loffler W, Maurer K, et al. Depression, negative symptoms, social stagnation and social decline in the early course of schizophrenia. *Acta Psychiatrica Scand* 1999; 100: 105-18.
12. Job DE, Whalley HC, Johnstone EC, Lawrie SM. Grey matter changes over time in high risk subjects developing schizophrenia. *Neuroimage* 2005; 25: 1023-1030.
13. Bilder MR, Reiter G, Bates J, et al. Cognitive development in schizophrenia: follow-back from the first episode. *J Clin Exp Neuropsychology* 2006; 28: 270-282.
14. Melle I, Larsen TK, Haahr U, et al. Reducing the duration of untreated first-episode psychosis. *Arch Gen Psychiatry* 2004; 61: 143-150.
15. McGorry PD, Yung AR, Phillips LJ, et al. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. *Arch Gen Psychiatry* 2002; 59: 921-928.
16. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the national comorbidity survey replication. *Arch Gen Psychiatry* 2005; 62: 593-602.
17. Thomsen PH. Schizophrenia with childhood and adolescent-onset – a nationwide register-based study. *Acta Psychiatrica Scand* 1996; 94: 187-193.
18. Lynskey M, White V, Hill D, Letcher T, Hall W. Prevalence of illicit drug use among youth: results from the Australian school students' alcohol and drugs survey. *Aust N Z J Public Health* 1999; 23: 519-524.
19. Costello EJ, Copeland W, Cowell A, Keeler G. Service costs of caring for adolescents with mental illness in a rural community, 1993-2000. *Am J Psychiatry* 2007; 164: 36-42.
20. Veit F, Sanci L, Coffey C, Young D, Bowes G. Barriers to adolescent health care: family physicians' perspectives. *J Adolesc Health* 1996; 18: 156.
21. Patton GC, Hetrick SE, McGorry P. Service responses for youth onset mental disorders. *Curr Opin Psychiatry* 2007; 20: 319-324.
22. Patton GC, Bowes G, Sawyer SM, Homel R, Stanley FJ. Towards a national agenda for youth? *Med J Aust* 2005; 183: 394-395.
23. Christiana JM, Gilman SE, Guardino M, et al. Duration between onset and time of obtaining initial treatment among people with anxiety and mood disorders: an international survey of members of mental health patient advocate groups. *Psychol Med* 2000; 30: 693-703.
24. Hirschfeld RM, Lewis L, Vornik LA. Perceptions and impact of bipolar disorder: how far have we really come? Results of the national depressive and

- manic-depressive association 2000 survey of individuals with bipolar disorder. *J Clin Psychiatry* 2003; 64: 161-174.
25. Hafner H, Maurer K, Loffler W, et al. Onset and early course of schizophrenia. In: Hafner H, Gattaz WF, eds. *Search for the causes of schizophrenia III*. Berlin: Springer Publishing; 1995: 43-66.
 26. Niemi LT, Suvisaari JM, Tuulio-Henriksson A, Lonnqvist JK. Childhood development abnormalities in schizophrenia: evidence from high-risk studies. *Schizophr Res* 2003; 60: 239-258.
 27. Davidson M, Reichenberg A, Rabinowitz J, Weiser M, Kaplan Z, Mark M. Behavioral and intellectual markers for schizophrenia in apparently healthy male adolescents. *Am J Psychiatry* 1999; 156: 1328-1335.
 28. Erlenmeyer-Kimling L, Cornblatt B. High-risk research in schizophrenia: a summary of what has been learned. *J Psych Res* 1987; 21: 401-411.
 29. Hafner H, Maurer K, Trendler G, et al. Schizophrenia and depression: challenging the paradigm of two separate diseases - A controlled study of schizophrenia depression and healthy controls. *Schizophr Res* 2005; 77: 11-24.
 30. Hafner H, Maurer K. Early detection of schizophrenia: current evidence and future perspectives. *World Psychiatry* 2006; 5: 130-138.
 31. Hafner H, Maurer K, Ruhrmann S, et al. Early detection and secondary prevention of psychosis: facts and visions. *Eur Arch Psychiatry Clin Neurosci* 2004; 254: 117-128,32.
 32. Hauser M, Pfennig A, Özgürdal S, Heinz A, Bauer M, Juckel G. Early recognition of bipolar disorder. *Eur Psych* 2007; 22: 92-98.
 33. Angst G, Gamma A, Endrass J. Risk factors for the bipolar and depression spectra. *Acta Psychiatr Scand* 2003; 108: 15-19.
 34. Akiskal HS, Maser JD, Zeller PJ, Endicott J, Coryell W, Keller M. Switching from 'unipolar' to bipolar II. An 11-year prospective study of clinical and temperamental predictors in 559 patients. *Arch Gen Psychiatry* 1995; 52: 114-123.
 35. Yung AR, Phillips LJ, Yuen HP, Francey SM, McFarlane CO, Hallgren M, McGorry PD. Psychosis prediction: 12 month follow up of a high-risk ('prodromal') group. *Schizophr Res* 2003; 60: 21-32.
 36. O'Toole BL. Screening for low prevalence disorders. *Aust N Z J Psychiatry* 2000; 34: S39-S46.
 37. Goldberg D, Thornicroft G. eds. *Mental health in our future cities*. Hove: Psychology Press 1998.
 38. Friedman RA. Uncovering an epidemic – screening for mental illness in teens. *New Engl J Med* 2006; 355: 2717-2719.
 39. Sanci LA, Kang MSL, Ferguson BJ. Improving adolescents' access to primary health care. *Med J Aust* 2005; 183: 416-417.
 40. Sanci LA, Sawyer SM, Kang MS-L, Haller DM, Patton GC. Confidential health care for adolescents: reconciling clinical evidence with family values. *Med J Aust* 2005; 183: 410-414.
 41. Bennett DL, Towns SJ, Elliott EJ. What is it going to take? Adolescent health in Australia. *Int J Adolesc Med Health* 2007; 19: 215-216.
 42. Council of Australian Governments. National action plan on mental health 2006-2011. 14 July 2006. Available at: www.coag.gov.au/meetings/140706/docs/nap_mental_health.pdf (accessed December 2007).
 43. Kang M, Bernard D, Usherwood T, et al. Towards better practice in primary health care settings for young people. *Health Promot J Austr* 2006; 17: 139-144.
 44. Swanton R, Collin P, Burns J, Sorensen I. Engaging, understanding and including young people in mental health services. *Int J Adolesc Med Health* 2007; 19: 325-332.
 45. Jorm AF, Kitchener BA, Kanowski LG, Kelly CM. Mental health first aid training for members of the public. *Int J Clin Health Psychol* 2007; 7: 141-151.
 46. Haller DM, Sanci LA, Patton GC, Sawyer SM. Toward youth friendly services: a survey of young people in primary care. *J Gen Intern Med* 2007; 22: 775-781.
 47. Johnson JG, Harris ES, Spitzer RL, Williams JBW. The patient health questionnaire for adolescents: validation of an instrument for the assessment of mental disorders among adolescent primary care patients. *J Adolesc Health* 2002; 30: 196-204.
 48. Andrews G, Peters L. The CIDI-Auto: A computerized diagnostic interview for psychiatry. World Health Organization Collaborating Centre for Mental Health and Substance Abuse 2001. Available at: www.crufad.unsw.edu.au/cidi (accessed December 2007)
 49. Coleman J, Wadsworth MEJ, Croudace TJ, Jones PB. Forty-year psychiatric outcomes following assessment for internalizing disorder in adolescence. *Am J Psychiatry* 2007; 164: 126-133.
 50. Merry SN. Prevention and early intervention for depression in young people – a practical possibility. *Curr Opin Psychiatry* 2007; 20: 325-329.
 51. Kennard B, Silva S, Vitiello B; The Tads Team. Remission and residual symptoms after short-term treatment in the treatment of adolescents with depression study (TADS). *J Am Acad Child Adolesc Psychiatry* 2006; 45: 1404-1411.
 52. Treatment for Adolescents With Depression study (TADS) team. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression. *JAMA* 2004; 292: 807-820.
 53. The TADS Team. The treatment for adolescents with depression study (TADS): long-term effectiveness and safety outcomes. *Arch General Psychiatry* 2007; 64: 1132-1144.
 54. Vitiello B, Rohde P, Silva S and the TADS Team. Functioning and quality of life in the treatment of adolescents with depression study (TADS). *J Am Acad Child Adolesc Psychiatry* 2006; 45:1419-1426.
 55. Morrison AP, French P, Parker S, et al. Three-year follow-up of a randomized controlled trial of cognitive therapy for the prevention of psychosis in people at ultrahigh risk. *Schizophr Bull* 2007; 33: 682-687.
 56. Woods S, Thomas L, Tully E, et al. Effects of oral glycine in the schizophrenia prodrome. *Schizophr Res* 2004; 70: 79-80.
 57. Lin PY, Su KP. A meta-analytic review of double-blind, placebo-controlled trials of antidepressant efficacy of omega-3 fatty acids. *J Clin Psychiatry* 2007; 68: 1056-1061.
 58. Monterrubio S, Solowij N, Meyer BJ, Turner N. Fatty acid relationships in former cannabis users with schizophrenia. *Prog Neuropsychopharmacol Biol Psychiatry* 2006; 30: 280-285.
 59. Satiz JA, Silverstein SM, McGovern KC, Schenkel L, Grant L. The neurosteroid prenenolone reduces negative symptoms in patients with schizophrenia: results of a preliminary double-blind study. *Schizophr Bull* 2007; 33: 458-459.
 60. Cornblatt BA, Lencz T, Smith CW, et al. Can antidepressants be used to treat the schizophrenia prodrome? Results of a prospective, naturalistic treatment study of adolescents. *J Clin Psychiatry* 2007; 68: 546-557.
 61. Gilbody SM, House AO, Sheldon TA. Routinely administered questionnaires for depression and anxiety: systematic review. *BMJ* 2001; 322: 406-409.
 62. Andrews G. Should depression be managed as a chronic disease? *BMJ* 2001; 322: 419-421.
 63. Andrews G, Teesson M. Smart versus dumb treatment: services for mental disorders. *Curr Opin Psychiatry* 1994; 7: 181-185.